Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the shares. The company’s Q4 update was highlighted by the announcement of the Nkure partnership to co-develop and co-commercialize CTX112 in India, the analyst tells investors in a research note. The firm says Crispr’s pipeline progress is on track.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics AG’s Financial Challenges: Sell Rating Due to Casgevy Program Burden
- Crispr Therapeutics AG: Strategic Collaborations and Promising Pipeline Drive ‘Buy’ Rating
- Crispr Therapeutics reports Q4 EPS (44c)
- Crispr Therapeutics price target raised to $86 from $85 at BofA
- Cathie Wood’s ARK Investment buys 187K shares of Crispr Therapeutics today